Crossject Société Anonyme (ALCJ.PA)
| Previous Close | 1.9780 |
| Open | 1.9900 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.9700 - 2.0150 |
| 52 Week Range | 1.5200 - 5.9600 |
| Volume | |
| Avg. Volume | 70,355 |
| Market Cap | 82.918M |
| Beta (5Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings Date | Sep 23, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.30 |
GlobeNewswireCrossject’s ZENEO® Auto-Injector's usability further demonstrated in extreme HAZMAT conditions
Crossject successfully completes a new U.S. summative human factors study to assess the usability of ZENEO® Midazolam, soon to be commercialized globally as ZEPIZURE®, under simulated chemical attack conditions. Rigorous HAZMAT (Hazardous Materials) dry-run involved 75 participants, who deployed 375 ZENEO® Midazolam auto-injectors in challenging conditions, including while wearing protective suits, without any handling problem.Study underscores ZENEO® Midazolam’s usability in extreme, high-risk
- GlobeNewswire
Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization
Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file for EUA early next year and to receive a positive FDA response shortly thereafterCrossject will manufacture additional product batches, including first commercial batches in early 2025, in anticipation of first BARDA deliveries later that year Dijon, France, October 22 2024 (07:30 CET) - Crossject (IS
